AMH与重型地中海贫血女孩原始卵泡密度及体外成熟结局的关联
该回顾性队列纳入119例接受卵巢组织冷冻保存的输血依赖型地中海贫血儿童及青少年女孩,分析术前血清AMH与组织学原始卵泡密度及卵巢组织卵母细胞体外成熟结局的关系。结果显示AMH与原始卵泡密度无显著相关,但与获卵数及IVM成熟率正相关。
要点
- AMH与原始卵泡密度无显著关联,不宜作为原始卵泡池的替代指标。
- AMH每升高1 ng/ml,获卵数增加14%,IVM成熟率提高3.50%。
- 年龄增长与原始卵泡密度降低、获卵数及成熟率改善相关。
核心结论
- 在输血依赖型地中海贫血儿童及青少年女孩中,血清AMH与组织学原始卵泡密度无显著相关,但与获卵数和IVM成熟率正相关。
研究设计与样本
- 回顾性队列研究,纳入2021年7月至2025年2月期间接受卵巢组织冷冻保存的119例输血依赖型地中海贫血儿童及青少年女孩。
主要发现
- 术前AMH中位数为3.1 ng/ml(四分位距1.9-4.4 ng/ml)。
- AMH与原始卵泡密度无显著关联(β=-0.04,95%CI:-0.12至0.03,P=0.262)。
- AMH与获卵数正相关(IRR=1.14,95%CI:1.08-1.20,P<0.001)。
- AMH与IVM成熟率正相关(β=3.50,95%CI:1.10-5.90,P=0.005)。
- 年龄增长与原始卵泡密度降低(β=-0.07,95%CI:-0.13至-0.01,P=0.032)、获卵数增加(IRR=1.06,95%CI:1.02-1.11,P=0.008)及成熟率提高(β=2.52,95%CI:0.54-4.51,P=0.013)相关。
临床怎么用
- AMH可用于咨询时预估卵巢组织卵母细胞体外成熟的获卵数与成熟率,但不应作为原始卵泡池的替代指标。
- AMH不应单独用于指导或改变生育力保存策略的临床决策,卵巢组织冷冻保存仍是儿童患者最成熟的选项。
局限性
- 回顾性设计及疾病特异性队列(输血依赖型地中海贫血)限制了对其他患者群体或健康个体的外推。
- AMH与原始卵泡密度的分离提示在生育力保存咨询中应谨慎解读AMH。
- 卵巢组织卵母细胞体外成熟仍属实验性技术,需前瞻性多中心研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the association between serum anti-Müllerian hormone (AMH) levels, primordial follicle density (PFD), and ovarian tissue oocyte in vitro maturation (OTO -IVM) outcomes in pediatric and adolescent girls undergoing ovarian tissue cryopreservation (OTC) for fertility preservation (FP)? SUMMARY ANSWER: In pediatric and adolescent girls undergoing FP, serum AMH levels were not correlated with histological PFD, but were positively associated with oocyte yield and IVM outcomes, with each 1 ng/ml increase in AMH corresponding to a 14% increase in oocyte yield and a 3.50% increase in the maturation rate of IVM. WHAT IS KNOWN ALREADY: Serum AMH is an established biomarker of ovarian reserve in adults, reflecting the number of antral follicles. However, its value as a surrogate of the primordial follicle pool in pediatric and adolescent girls remains uncertain due to limited data. STUDY DESIGN, SIZE, DURATION: This retrospective cohort study included 119 pediatric and adolescent girls with transfusion-dependent thalassemia (TDT) who underwent OTC between July 2021 and February 2025. PARTICIPANTS/MATERIALS, SETTING, METHODS: The study included 119 girls with TDT undergoing FP prior to hematopoietic stem cell transplantation. Preoperative serum AMH levels were measured. Ovarian cortical tissue was obtained for OTC, with a small fraction analyzed histologically for PFD. Immature oocytes retrieved from the tissue underwent IVM. Multivariate regression analyses evaluated associations between AMH, PFD, oocyte yield, and oocyte maturation rates. MAIN RESULTS AND THE ROLE OF CHANCE: Median preoperative AMH was 3.1 ng/ml (interquartile range: 1.9-4.4 ng/ml). AMH was not significantly associated with PFD (β = -0.04, 95% confidence interval [CI]: -0.12 to 0.03, P = 0.262). Higher AMH was positively correlated with increased oocyte yield (incidence rate ratio [IRR]: 1.14, 95% CI: 1.08-1.20; P < 0.001) and improved maturation rates of IVM (β = 3.50, 95% CI: 1.10-5.90; P = 0.005). Increasing age was associated with lower PFD (β = -0.07, 95% CI: -0.13 to -0.01, P = 0.032) and improved oocyte retrieval (IRR: 1.06, 95% CI: 1.02-1.11; P = 0.008) and maturation rates (β = 2.52, 95% CI: 0.54-4.51; P = 0.013). LIMITATIONS, REASONS FOR CAUTION: The study's limitations include the retrospective design and the disease-specific TDT cohort, limiting generalizability to other patient groups or healthy individuals. The dissociation between AMH and PFD indicates that AMH should be interpreted cautiously in FP counseling. As OTO-IVM remains experimental, AMH alone is insufficient to guide fertility preservation decisions, and OTC remains the most established option in pediatric patients. WIDER IMPLICATIONS OF THE FINDINGS: In children and adolescents with TDT, AMH is positively associated with IVM outcomes. It may be informative when counseling patients and families about the expected performance of OTO-IVM, particularly relevant in settings such as hematologic malignancies, where ovarian tissue transplantation may be contraindicated. However, AMH should neither be considered as a surrogate for the primordial follicle pool nor used to guide or alter clinical decision-making regarding fertility preservation strategies. Further prospective, multicenter studies are necessary to validate these findings. FUNDING: No external funding was received for this study. DISCLOSURES: The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Zhao W, Liu X, Guo Y, et al. Associations of anti-Müllerian hormone with primordial follicle density and in vitro maturation outcomes in girls with transfusion-dependent thalassemia undergoing fertility preservation. Hum Reprod. 2026. PMID: 42515819. doi:10.1093/humrep/deag117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。